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Inflammation plays a central pathogenic role in the pernicious metabolic and end-organ
sequelae of obesity. Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has
become the most common chronic liver disease in the developed world. The twinned obser-
vations that obesity is associated with increased activation of the interleukin (IL)-17 axis
and that this axis can regulate liver damage in diverse contexts prompted us to address the
role of IL-17RA signaling in the progression of NAFLD. We further examined whether
microbe-driven IL-17A regulated NAFLD development and progression. We show here that
IL-17RA2/2 mice respond to high-fat diet stress with significantly greater weight gain, vis-
ceral adiposity, and hepatic steatosis than wild-type controls. However, obesity-driven lipid
accumulation was uncoupled from its end-organ consequences in IL-17RA2/2 mice, which
exhibited decreased steatohepatitis, nicotinamide adenine dinucleotide phosphate
(NADPH)-oxidase enzyme expression, and hepatocellular damage. Neutralization of IL-
17A significantly reduced obesity-driven hepatocellular damage in wild-type mice. Further,
colonization of mice with segmented filamentous bacteria (SFB), a commensal that induces
IL-17A production, exacerbated obesity-induced hepatocellular damage. In contrast, SFB
depletion protected from obesity-induced hepatocellular damage. Conclusion: These data
indicate that obesity-driven activation of the IL-17 axis is central to the development and
progression of NAFLD to steatohepatitis and identify the IL-17 pathway as a novel thera-
peutic target in this condition. (HEPATOLOGY 2014;59:1830-1839)
See Editorial on Page 1671
O
besity has become a full-fledged pandemic.1
Inflammation is central to the pathogenesis of
the metabolic and end-organ sequelae of obe-
sity, including nonalcoholic fatty liver disease
(NAFLD).2 NAFLD represents a spectrum of disorders
that range from nonalcoholic steatosis (NAFL) to non-
alcoholic steatohepatitis (NASH) to cirrhosis.3 In the
U.S., one-third of adults have evidence of steatosis.
The prevalence of NASH is lower, affecting 2%-3% of
adults and children.4 That said, up to 25% of those
with NASH progress to cirrhosis.5 Despite its clinical
and public health significance, the immunopathogenesis
of NAFLD, in particular those mechanisms leading to
development of steatohepatitis, remains underdefined.
Interleukin (IL)-17A and IL-17F are closely related
cytokines that play essential roles in barrier immunity to
bacterial and fungal infection.6 Dysregulated production
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of these IL-17 family members also appears to drive
inflammatory pathology in various autoimmune dis-
eases.6 Both IL-17A and IL-17F signal through a com-
plex consisting of IL-17RA and IL-17RC. In addition,
IL-17E signals through a complex consisting of IL-17RA
and IL-17RB.6 The ability of IL-17 signaling to induce
the production of cytokines and neutrophil chemokines
is central to their biological effects.
Obesity is associated with increased IL-17A production
in humans.7 Mirroring this, T helper (Th)17 cell expan-
sion is observed in obese mice.8 In response to caloric
excess, mice lacking IL-17A exhibit protection from glu-
cose dysmetabolism, despite increased weight gain.9 The
IL-17 axis has also been linked to hepatic injury: an
increased frequency of IL-17A-expressing cells (and
increased IL-17A expression) in diverse human liver dis-
eases and mouse models of liver injury.10 Further, IL-17A
neutralization or genetic deletion of IL-17A has been
shown to be protective in mouse models of acute hepati-
tis,11 drug-induced liver injury,12 and lipopolysaccharide
(LPS)-induced liver injury during high-fat diet stress.13
IL-17RA is widely expressed in the liver and IL-17 drives
neutrophil chemokine expression by such cells.10 Of note,
an increased hepatic neutrophil/lymphocyte ratio is pre-
dictive of NAFLD progression,14 and neutrophilic inflam-
mation has been described in human NASH.15
Given that IL-17 is induced during obesity, and
given the observed linkage between IL-17 induction
and hepatic inflammation and damage, we hypothe-
sized that activation of the IL-17 axis might causally
contribute to NAFLD pathogenesis. The current stud-
ies provide, to our knowledge, the first evidence for a
critical role for IL-17RA signaling in driving NAFLD
progression, as well as the first report of a role for
microbe-driven IL-17 production in exacerbating hepa-
tocellular damage in NAFLD. Specifically, genetic dele-
tion of IL-17RA as well as antibody-mediated
neutralization of IL-17A led to protection from steato-
hepatitis, nicotinamide adenine dinucleotide phosphate
(NADPH)-oxidase activation, and hepatocellular dam-
age in mouse models of obesity-induced NAFLD. Fur-
thermore, colonization of mice with segmented
filamentous bacteria (SFB), a bacterium known to aug-
ment IL-17 production, exacerbated and accelerated
hepatocellular damage, whereas depletion of SFB led to
protection from obesity-induced hepatocellular damage.
Materials and Methods
Mice. All mice were on a C57BL/6 background. All
studies were approved by the Cincinnati Children’s Hos-
pital Medical Center (CCHMC) Institutional Animal
Care and Use Committee (IACUC). Wild-type (WT)
mice and IL-17RA2/2 mice (Amgen) were bred at
CCHMC. For SFB colonization/depletion studies, mice
were obtained from Jackson Labs or Taconic Farms.
Obesity Models. Diets: Mice were fed either a
high-fat diet (HFD; Research Diets #D12492) or a
chow diet (Chow; LAB Diet #5010). Glucose dysme-
tabolism: Fasting glucose and insulin and glucose toler-
ance testing were quantified after an overnight fast.
Liver: Hepatic triglycerides were quantified using Tri-
glyceride Reagent and Triglyceride Standards (Pointe
Scientific); serum alanine transaminase (ALT) levels
were quantified using ALT Reagent and Catatrol I and
II (Catachem); lipid peroxidation was quantified using
4-hydroxynonenal (4-HNE) enzyme-linked immuno-
sorbent assay (ELISA) reagents (Cell Biolabs)—all
according to the manufacturer’s instructions.
Histology. Liver and gut tissue were fixed in 10%
buffered formalin and stained with hematoxylin and
eosin (H&E).
Quantitative Reverse-Transcription Polymerase
Chain Reaction (qRT-PCR). Tissue samples were
homogenized in TRIzol, RNA was extracted, reverse
transcribed to complementary DNA (cDNA), and sub-
jected to qPCR analysis (Light Cycler 480 II; Roche).
For bacterial quantification and colonization, fecal and
intestinal DNA was extracted by way of TissueLyser
(Qiagen)-mediated lysis and levels of 16S DNA were
quantified by qPCR.
SFB Colonization/Depletion. Mice were colonized
by way of oral gavage of fecal material dissolved in
phosphate-buffered saline (PBS). SFB depletion was
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achieved by way of vancomycin treatment (0.5 g/L;
Fisher) in drinking water.
Hepatic Immune Infiltration. Single cell suspen-
sions were isolated as described16 and stained with
directly conjugated monoclonal antibodies or isotype
controls (all eBioscience). Data were collected using an
LSRII flow cytometer and analyzed by FlowJo software.
Limulus Amebocyte Lysate (LAL) Assay. Systemic
endotoxin levels were quantified using the LAL assay
(Lonza) according to the manufacturer’s instruction.
In Vivo Cytokine Capture Assay. Systemic IL-
17A, tumor necrosis factor (TNF), IL-6, and
interferon-gamma (IFN-c) levels were detected using
the in vivo cytokine capture assay,17 employing biotin-
ylated capture antibodies (eBioscience).
Statistical Analysis. Data were analyzed by analy-
sis of variance (ANOVA) followed by Tukey’s correc-
tion, unpaired Student t test, or by comparing
intercepts of linear regression equations implemented
in Prism 5a (GraphPad Software). For data failing
Fig. 1. IL-17RA deficiency exacerbates HFD-induced obesity but protects from glucose dysmetabolism. Eight-week-old male IL-17RA2/2 mice
and WT controls (n 5 4-12/condition) were placed on an HFD or chow. (A) Body weight. (B) Body weight gain over 20 weeks. (C) Epididymal
white adipose tissue (eWAT) weight. (D) Fasting glucose. (E) Glucose tolerance test. (F) Insulin tolerance test. A representative of two separate
experiments. (A), AUC ANOVA *P < 0.0001; (B,C) and (E,F), ANOVA *P < 0.001; (D), ANOVA *P < 0.03; (A-F), Tukey’s correction *P < 0.05,
**P < 0.01; ***P < 0.001.
Fig. 2. IL-17A signaling by way of IL-17RA exacerbates hepatocellular damage during HFD-induced obesity. Eight-week-old male IL-17RA2/2
mice and WT controls (n 5 4-12/condition) were placed on an HFD or chow. (A) Hepatic triglyceride levels. (B) Serum ALT levels. Analysis done
after 20 weeks of HFD feeding. (C) Neutralization of IL-17A protects from HFD-induced hepatocellular damage. Mice were treated intraperitone-
ally once a week for 3 weeks, with 250 lg/mouse of anti-IL-17A or isotype control. Treatment started at week 12 of HFD stress and ALT was
quantified at week 15. (A,B) Representative of two separate experiments. (C) A single experiment. (A), ANOVA *P < 0.001; (B), ANOVA *P <
0.003; (C), ANOVA *P < 0.02. (A-C), Tukey’s correction *P < 0.05, **P < 0.01; ***P < 0.001.
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(a 5 0.01) the D’Agostino-Pearson Omnibus test for
normality, the Mann-Whitney test or Kruskal-Wallis
test with Dunn’s multiple testing correction was used.
All values are represented as means 6 SE.
Results
Integral Role of IL-17 Signaling in the Pathogene-
sis of NAFLD. To define the contribution of IL-17
signaling to the progression of NAFLD, IL-17RA2/2
and WT mice were challenged in a standard model of
HFD-induced obesity—a model that induces obesity
along with steatosis and hepatocellular damage. Under
these conditions, IL-17RA2/2 mice exhibited signifi-
cantly increased body weight and weight gain, white
adipose tissue (WAT) weight, and systemic leptin levels
relative to WT controls (Fig. 1A-C; Supporting Fig.
1A). However, IL-17RA2/2 mice were protected from
glucose dysmetabolism (fasting hyperglycemia, glucose
intolerance, and insulin resistance; Fig. 1 D-F) and,
despite significant increases in hepatic triglyceride
deposition (Fig. 2A) and a trend towards increased
total liver weight (Supporting Fig. 1B), were protected
from hepatocellular damage, as quantified by analysis
of serum ALT concentrations (Fig. 2B). No differences
in daily food intake were observed between WT and
IL-17RA2/2 mice subjected to HFD stress (Support-
ing Fig. 1C). Of note, antibody-mediated neutraliza-
tion of IL-17A conferred protection from
hepatocellular damage in WT mice challenged with an
HFD, specifically implicating IL-17A, among the
diverse IL-17 family member ligands for IL-17RA, in
obesity-related hepatocellular damage (Fig. 2C).
To assess the robustness of these findings, we
employed an additional model of NAFLD: challenge
with a high-carbohydrate, high medium-chain trans fat
diet (HFHCD), a model that induces a broader spec-
trum of NAFLD.16 Challenge of WT mice with an
HFHCD resulted in increased IL-17A and decreased
IL-17RA hepatic messenger RNA (mRNA) expression,
Fig. 3. Increased steatosis but decreased steatohepatitis in IL-17RA2/2 mice on an HFD. Representative liver histology (H&E staining) after
20 weeks on chow or HFD. (A) Marked difference in the amount and type of steatosis between WT and IL-17RA2/2 mice on HFD. HFD stress
drives steatosis, mostly located in zone 3 (outlined in white), with sparing of zone 1 (white circles) in WT controls. In contrast, IL-17RA2/2 mice
show increased overall steatosis that is predominantly located in zones 2 and 3. No histological difference is observed on RD. (B) Decreased
steatohepatitis in IL-17RA2/2 mice. Multiple foci of lobular inflammation with clusters of inflammatory cells (white arrows) in the livers of WT
mice on HFD. Higher magnification (403) depicts the inflammatory focus in WT mice (black circle). Hepatic immune infiltration (C) total cells
(CD451), (D) CD451Gr11 cells, and (E) CD451CD11b1 cells. (F) Hepatic qRT-PCR expression of neutrophil recruiting chemokine, CXCL1.
(C,D), Student t test; (F) ANOVA *P < 0.004; Tukey’s correction *P < 0.05, ***P < 0.001.
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along with increased recruitment of Gr-11 cells into the
liver (data not shown). As seen with HFD challenge, IL-
17RA2/2 mice exhibited increased body weight and
weight gain, adiposity, hepatic weight, and hepatic tri-
glyceride deposition, but were protected from glucose
dysmetabolism and hepatocellular damage (Supporting
Fig. 2). Further, kinetic analysis of serum ALT levels
revealed that the lack of IL-17RA led to sustained pro-
tection from hepatocellular damage (Supporting Fig.
2L). Taken together, these data provide strong evidence
that the IL-17 axis regulates disease progression in obe-
sogenic mouse models of NAFLD.
Regulation of Hepatic and Systemic Inflammatory
Responses by the IL-17 Axis During Obesity. We
also examined the progression of steatosis to steatohe-
patitis in WT and IL-17RA2/2 mice. Of interest,
despite increased weight gain and hepatic triglyceride
accumulation, IL-17RA2/2 mice were resistant to the
development of steatohepatitis, as determined by the
absence of foci of inflammatory cells in IL-17RA2/2
compared to WT controls (Fig. 3A,B). Similarly,
HFD-challenged IL-17RA2/2 mice exhibited
decreased infiltration of immune cells in the liver—
something attributed to reduced infiltration of Gr-11
cells and CD11b1 cells (Fig. 3C-E; Supporting
Figs. (3 and 4)). Further, reduction in immune infiltra-
tion correlated with reduced hepatic expression of
mRNA for the neutrophil chemokines CXCL1 and
CXCL2, CXCL12, G-CSF along with mRNA for
Alox5, an enzyme critical for production of the neu-
trophil chemoattractant LTB4 (Fig. 3F; Supporting
Fig. 5). Of note, HFD-challenged IL-17RA2/2 mice
also exhibited decreased mRNA expression of markers
of myeloid cell infiltration and expression of other
inflammatory mediators (Supporting Fig. 5).
Although the molecular mechanisms that regulate
hepatocellular damage during NAFLD are not well
understood, the most favored hypothesis suggests that
steatosis sensitizes hepatocytes to subsequent inflamma-
tory- and/or reactive oxygen species (ROS)-driven oxi-
dative stress-mediated hepatocellular injury and
fibrosis.18 Of note, it is well established that: (1) IL-
17A mediates neutrophil-dependent hepatocellular
damage19; (2) IL-17A can drive ROS production20;
and (3) infiltrating neutrophils and/or inflammation-
associated ROS production can induce hepatic paren-
chymal cell injury.21,22 Therefore, as activated neutro-
phils and Kupffer cells produce high amounts of ROS
by way of NADPH oxidase cascade, we quantified
hepatic expression of NADPH oxidase components in
WT and IL-17RA2/2 mice. As shown, IL-17RA2/2
mice on HFD had significantly decreased hepatic
Nox2, p22phox, p47phox, and p67phox mRNA expres-
sion, along with decreased lipid peroxidation as quan-
tified by hepatic 4-HNE concentrations compared to
WT controls (Fig. 4). These data suggest that the IL-
17 axis, by regulating hepatic immune infiltration/
inflammation, also modulates hepatic NADPH
oxidase-dependent ROS production and lipid peroxi-
dation—providing a clear downstream candidate
mechanism for IL-17-mediated exacerbation of hepato-
cellular damage in this context.
HFD feeding is reported to increase circulating endo-
toxin levels,23 something also associated with NASH
pathogenesis.24 We thus quantified serum endotoxin
concentrations in WT and IL-17RA2/2 mice fed chow
and HFD, and examined the ability of IL-17RA2/2
mice to respond to LPS challenge. As shown, although
HFD feeding did increase systemic endotoxin levels, sig-
nificant differences between WT and IL-17RA2/2 were
not observed (Fig. 5A). It is noted that systemic meas-
urements may miss differences in portal vein endotoxin
Fig. 4. IL-17RA2/2 mice exhibit decreased expression of enzymes
driving hepatic ROS production during HFD stress. Hepatic mRNA
expression of NADPH oxidase components and hepatic lipid peroxida-
tion after 20 weeks on diet, (A) Nox2, (B) p22phox, (C) p47phox, (D)
p67phox, and (E) 4-HNE. Represents a single experiment; (A-E),
ANOVA *P < 0.0001; Tukey’s correction *P < 0.05, **P < 0.01;
***P < 0.001.
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levels. We further examined whether IL-17RA signaling
regulates LPS-driven production of proinflammatory
cytokines during HFD stress. IL-17RA2/2 mice had
comparable levels of proinflammatory and immunore-
gulatory cytokines following LPS challenge when fed
chow diet—as quantified by a cytokine capture assay
that integrates in vivo cytokine production over the 24-
hour period of challenge.17 However, under HFD stress,
IL-17RA2/2 mice exhibited decreased levels of LPS-
stimulated proinflammatory and immunoregulatory
cytokines compared to WT controls (Supporting Fig.
6). In addition, as IL-17RA is required for maintenance
of baseline neutrophil counts in mice,25 we examined
whether this contributed to protection from NAFLD
progression. Although IL-17RA deficiency was associ-
ated with decreased peripheral blood neutrophil and
monocyte concentrations at baseline, such differences
were obviated by obesogenic-diet stress (Supporting Fig.
7). Together, these suggest that IL-17 signaling leads to
increased responsiveness to inflammatory stimuli and
recruitment of neutrophils and/or myeloid cells to the
liver during obesogenic dietary stress.
Contribution of SFB to IL-17 Induction in
NAFLD Models. The role of IL-17 signaling in intes-
tinal barrier immunity and inflammation is well estab-
lished.6 Thus, we examined whether the observed
differences between the IL-17RA2/2 and WT mice
were secondary to alterations in intestinal inflamma-
tion. Histological examination of the small and large
intestines revealed no inflammatory infiltrates during
either HFD or HFHCD challenge (Fig. 5B,C; Sup-
porting Fig. 8).
Variations in the intestinal microbiota have previ-
ously been associated with both obesity and
NAFLD.26 Indeed, a (transferable) dysbiotic micro-
biome has been shown to contribute to the develop-
ment of steatosis and hepatocellular damage.27 To
date, however, the move from association to causation
has not been made. In other contexts where gut-
derived IL-17 significantly contributes to physiology
(gut immune system maturation) or pathophysiology,
an individual pathobiont has been causally implicated:
SFB is capable of inducing robust IL-17A production
in the gut, with local and systemic consequences.28,29
Not surprisingly, given the described role for SFB-
mediated induction of Th17-associated barrier immu-
nity, IL-17RA2/2 mice exhibited a significant increase
in the relative abundance of SFB, without marked dif-
ferences in total Eubacteria, as determined by qPCR
for 16S rDNA (Fig. 5D,E).
Since both SFB colonization and obesity have been
described to induce IL-17 production,9,28 we sought
to determine whether such effects were additive. As
shown in Fig. 6A, SFB-negative WT mice exhibited
increased serum IL-17A subsequent to HFD challenge.
Notably, SFB colonization augmented IL-17A
Fig. 5. Lack of IL-17RA does not alter metabolic endotoxemia or result in frank intestinal inflammation during HFD stress, but does lead to
alterations in the gut microbiota. (A) Systemic endotoxin levels after 20 weeks on diet (n 5 4-12/condition). (B) IL-17RA2/2 mice and WT con-
trols (n 5 3/condition) were placed on an HFD or chow for 16 weeks and intestinal inflammation was quantified. (C) Representative histology
(H&E staining) of quantified intestinal tissue. (D) Total Eubacterial DNA levels in the terminal ileum of 6-week-old chow-fed WT and IL-17RA2/2
mice (n 5 6-7). (E) SFB levels. Represents a single experiment. (A,E), Student t test *P < 0.05; **P < 0.01.
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production in mice placed on an HFD. SFB-positive
mice exhibited IL-17A levels in excess of those
observed in SFB-negative mice. This was true regard-
less of the source of SFB—whether from the complete
fecal microbiota of WT mice obtained from Taconic
Farms,28 or that from SFB mono-associated mice.30
In order to examine the effects of SFB-induced aug-
mentation of IL-17A production on obesity-associated
hepatocellular damage, SFB-negative WT mice were
colonized with SFB. Colonization was confirmed/
quantified by qRT-PCR on fecal pellets (Fig. 6B).
With HFD challenge, despite similar body weights
and hepatic triglyceride accumulation, these mice
exhibited a significant increase in markers of hepatocel-
lular damage (Fig. 6C-E), indicating that SFB coloni-
zation augments hepatocellular damage in this model.
Of note, no other marked phenotypic differences were
observed in SFB colonized mice in comparison with
mock-colonized controls (Supporting Fig. 9).
To examine the converse, we ablated SFB coloniza-
tion in WT mice using vancomycin, an antibiotic
shown to reverse SFB-mediated induction of Th17
polarization in vivo.31 Such antibiotic treatment is,
perforce, nonspecific, and may lead to broad disrup-
tion of microbial community structure.32 Indeed,
vancomycin-treated mice exhibited cecal enlargement
(Supporting Fig. 10), a finding observed with a variety
of antibiotic treatments.28 Nonetheless, vancomycin
treatment led to decreased serum IL-17A levels (Fig.
7A), depleted SFB colonization (Fig. 7B), and reduced
HFD-mediated hepatocellular damage (Fig. 7E), with-
out affecting body weight or hepatic triglyceride accu-
mulation (Fig. 7C,D). No other phenotypic
differences were observed in vancomycin-treated mice
when compared with control-treated mice (Supporting
Fig. 10).
We similarly sought to assess the extent to which
SFB-associated increases in IL-17A production might
affect the development of hepatocellular damage in the
context of excess energy intake during chow feeding.
For this, Leprdb/db mice were colonized with SFB. We
found that SFB-colonized Leprdb/db mice exhibited rel-
ative protection from the development of obesity (Fig.
8A), something consonant with the known role of IL-
17A in restraining weight gain in diet-induced obe-
sity.9 In contrast, SFB-colonized Leprdb/db mice
achieved parity with their SFB-negative counterparts
with regard to the level of hepatocellular damage,
despite their relative leanness (Fig. 8B). Direct com-
parison of weight and serum ALT concentrations
Fig. 6. SFB colonization elevates serum IL-17A and induces obesity-associated hepatocellular damage. Mice from Jackson Labs were colon-
ized by way of oral gavage with either autologous SFB-negative fecal material from Jackson Labs (Jax) or exogenous SFB-positive fecal material
from C57BL/6 mice from Taconic Farms (Tac) or from C57BL/6 mice monocolonized with SFB (SFB Mono). (A) IL-17A levels determined after
12 weeks of HFD challenge. (B) Fecal SFB levels at the initiation of HFD feeding. (C) Body weight. (D) Hepatic triglyceride levels. (E) Serum ALT
levels. Represents a single experiment. (A) (n 5 3 chow group; n 5 7-11/condition HFD groups). (C-E) (n 5 6-9/condition). ANOVA; *P <
0.03; Tukey’s correction *P < 0.05. (B,E), Student t test *P < 0.05.
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demonstrated significant SFB colonization-associated
augmentation of hepatocellular damage in Leprdb/db
mice (Fig. 8C). Of interest, SFB-colonized Leprdb/db
mice did not eat less than their mock-colonized coun-
terparts and did not exhibit other substantial pheno-
typic differences (Supporting Fig. 11).
Discussion
Taken together, our data represent the first evidence
for a critical role for IL-17RA signaling in driving
NAFLD progression. Specifically, our data suggest a
model in which induction of the IL-17 axis exacerbates
and accelerates hepatocellular damage in the context of
obesity and established steatosis, driving the progres-
sion from steatosis to steatohepatitis. Our data also
underscore the potential for specific components of the
gut microbiota to drive this progression: SFB coloniza-
tion augments systemic IL-17A concentrations, associ-
ated with increased hepatocellular damage, in the
context of obesity.
Our data imply that SFB mediates its effects on
murine NAFLD by way of its effects on induction of
IL-17 signaling, consonant with the role of SFB in
Fig. 7. SFB depletion reduces serum IL-17A and suppresses obesity-associated hepatocellular damage. Mice from Taconic Farms (n 5 6-29/
condition) were treated with vancomycin in their water or mock-treated and fed either HFD or chow for 16 weeks. (A) Serum IL-17A levels. (B)
Fecal SFB levels at the initiation of HFD feeding. (C) Body weight. (D) Hepatic triglyceride levels. (E) Serum ALT levels. A representative of two
separate experiments. (A,B), Student t test *P < 0.05; ***P < 0.001. (E), Mann-Whitney test *P < 0.05.
Fig. 8. SFB colonization of chow-fed genetically obese, Leprdb/db mice protects from weight gain but accelerates hepatocellular damage. (A)
Body weight. (B) Serum ALT levels. (C) Hepatocellular damage (ALT) expressed as a function of body weight. A representative of two separate
experiments (n 5 5-6/condition). (A), AUC ANOVA *P < 0.0001; Tukey’s correction *P < 0.01. (C), P < 0.001; linear regression line intercepts
are significantly different.
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driving extraintestinal pathology through activation of
the IL-17 axis in other mouse models of inflammatory
disease.28 Current data suggest that SFB is a patho-
biont in humans as it is in mice, being developmen-
tally regulated in both species.33 If SFB plays a similar
role in human NAFLD, it may be that individuals
with hepatic steatosis who develop progressive NAFLD
might do so as a consequence of first developing mal-
adaptive immune responses and/or dysbiosis early in
life. Examples of similar developmental predispositions
have been cataloged for other pathophysiologic
states.34 Further, based on our findings, it is a reasona-
ble hypothesis that the classes and/or species of bacte-
ria that drive to hepatocellular damage in human
NAFLD likely also induce IL-17. Of interest, infection
with Clostridium difficile, a close relative of SFB, indu-
ces IL-1735 and has also been associated as an inde-
pendent risk factor for adverse outcomes in patients
with cirrhosis.36
Further, our data lay the foundation for future inves-
tigation of the key cellular and molecular mechanisms
underlying the contributions of the IL-17 axis and the
gut microbiota to NAFLD progression. Specifically, the
relevant source(s) of IL-17A production, the critical IL-
17RA-expressing cell type(s), the critical immune-
infiltrating cells in the liver, and the underlying cellular
effector mechanisms remain to be defined. IL-17A is
predominantly produced by Th17 cells, with contribu-
tions from other ab T cell subsets.6 Many of these cell
types are abundant within the liver itself or in close
apposition to it. In terms of the receptor, a plethora of
liver-resident cells express IL-17RA.10 Our current
understanding of NASH pathogenesis is most compati-
ble with an important role for IL-17RA expression by
Kupffer cells or hepatic stellate cells but not hepato-
cytes, hepatic endothelial cells, or neutrophils.37-39
However, future studies using cell type-specific deletion
of IL-17RA will be essential for determining the critical
IL-17RA-expressing cell type(s) important in driving
the progression of NAFL to NASH.
Our data also suggest that IL-17RA signaling regu-
lates neutrophil and monocyte recruitment to the liver
during HFD stress—something associated with altered
activation of the NADPH oxidase cascade, lipid peroxi-
dation, and, presumably, hepatocellular damage.7,25,26
These findings lay the foundation for future studies
focused on defining the role of neutrophils and
monocyte-derived cells, as well as the role of ROS and
mitochondrial damage, in IL-17 axis-driven NASH
pathogenesis.
The relevance of these data from mouse models to
human disease needs validation. Of note, the association
of IL-17 axis activation with diverse human liver dis-
eases,10 along with the association of single nucleotide
polymorphisms (SNPs) in and near genes important to
the IL-17 axis (e.g., STAT4 and RORA) in humans
with increases in serum levels of a marker of hepato-
biliary disease, both suggest the relevance of the IL-17
axis in human NAFLD.40,41 Further, in humans it has
been shown that: (1) NASH correlates with elevated
expression of IL-1713; (2) neutrophilic inflammation
of the liver15 and an increased hepatic neutrophil/lym-
phocyte ratio is predictive of the progression of
NAFLD to NASH14; and (3) patients with NASH
exhibit structural abnormalities in hepatocyte mito-
chondria and exacerbated ROS production.42
In sum, our findings implicate IL-17 signaling as a
causal contributor to the progression of NAFLD to
steatohepatitis, identify a specific species of commensal
bacteria that is capable of driving both IL-17 produc-
tion and hepatocellular damage, and suggest novel can-
didate therapeutic approaches for NASH. The latter is
of significant relevance as efforts are under way to
move anti-IL17 therapeutics into the clinic43 for the
treatment of autoimmune inflammation, while oral
vancomycin has been shown to reduce serum markers
of hepatocellular damage in primary sclerosing cholan-
gitis,44 another inflammatory condition leading to cir-
rhosis. Targeting of the IL-17 axis by way of either of
these approaches may represent a novel therapeutic
approach to NAFLD.
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